Published in Br J Cancer on September 16, 2008
Molecular Epidemiology of Lung Adenocarcinoma in Multi-ethnic Asian Phenotype | NCT01774526
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer (2009) 3.37
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res (2009) 2.01
HGF-independent potentiation of EGFR action by c-Met. Oncogene (2011) 1.46
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med (2012) 1.27
Cancer genes in lung cancer: racial disparities: are there any? Genes Cancer (2012) 1.12
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer Res (2011) 1.04
Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS One (2013) 1.03
The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents. Oncologist (2013) 0.98
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol (2015) 0.97
The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res (2009) 0.96
The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. Cell Death Dis (2013) 0.95
A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma. Genes Cancer (2010) 0.93
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity. Oncogene (2008) 0.90
An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer. Cancer (2011) 0.89
Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation. Oncotarget (2015) 0.87
Met interacts with EGFR and Ron in canine osteosarcoma. Vet Comp Oncol (2011) 0.86
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. Br J Cancer (2014) 0.85
Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC Cancer (2011) 0.85
Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming. Oncotarget (2016) 0.84
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts. Oncol Rep (2011) 0.84
Does hepatocyte growth factor/c-Met signal play synergetic role in lung cancer? J Cell Mol Med (2010) 0.84
The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer. Oncotarget (2016) 0.83
Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results. Isr J Chem (2012) 0.83
Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug development. PLoS One (2014) 0.83
Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis. Int J Med Sci (2013) 0.82
MET inhibition in lung cancer. Transl Lung Cancer Res (2013) 0.82
Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. Ann Transl Med (2015) 0.81
Lung cancer in never smokers. Semin Respir Crit Care Med (2011) 0.81
Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa. PLoS One (2012) 0.80
Efficiently prepared ephedrine alkaloids-free Ephedra Herb extract: a putative marker and antiproliferative effects. J Nat Med (2016) 0.80
Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation. Clin Exp Metastasis (2012) 0.79
Targeted Therapies in Lung Cancer. Surg Pathol Clin (2010) 0.78
MET targeted therapy for lung cancer: clinical development and future directions. Lung Cancer (Auckl) (2012) 0.78
Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells by Inducing Apoptosis. J Cancer Prev (2015) 0.78
Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer. Br J Cancer (2011) 0.78
Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification. Cancer Sci (2014) 0.77
Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors. ACS Med Chem Lett (2014) 0.77
MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer. J Carcinog (2009) 0.76
Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells. MAbs (2016) 0.76
Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer. Clin Transl Med (2014) 0.76
Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy. Exp Mol Med (2017) 0.75
TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells. Cell Death Dis (2016) 0.75
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol (2017) 0.75
ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients. Transl Lung Cancer Res (2013) 0.75
Analysis of circulating adipokines in patients newly diagnosed with solid cancer: Associations with measures of adiposity and tumor characteristics. Oncol Lett (2017) 0.75
Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates. J Biol Chem (2016) 0.75
Special issue: "MET as actionable target in cancer therapy". Ann Transl Med (2017) 0.75
The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models. Am J Cancer Res (2017) 0.75
Combined treatment with MET inhibitors and other therapies in lung cancer. Transl Lung Cancer Res (2012) 0.75
MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition. PLoS One (2017) 0.75
A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models. Oncol Ther (2016) 0.75
Multiplexed tyrosine kinase activity detection in cancer cells using a hydrogel immobilized substrate. Anal Bioanal Chem (2013) 0.75
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A (2006) 5.23
Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A (2008) 5.08
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell (2007) 4.85
Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov (2008) 4.76
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res (2005) 4.13
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet (2005) 4.00
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer (2006) 3.92
Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A (2007) 3.63
Targeting the c-Met signaling pathway in cancer. Clin Cancer Res (2006) 3.57
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res (2003) 3.47
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett (2004) 3.17
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res (2007) 2.83
c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev (2003) 2.81
Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res (2007) 2.78
An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res (2005) 2.72
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther (2008) 2.58
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene (2003) 2.54
A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res (2006) 2.48
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res (2003) 2.39
Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res (2007) 2.30
The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol (2007) 2.02
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res (2002) 1.82
Cancer therapy: can the challenge be MET? Trends Mol Med (2005) 1.81
The Met proto-oncogene mesenchymal to epithelial cell conversion. Science (1994) 1.77
Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res (1998) 1.66
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol (2006) 1.55
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res (2005) 1.50
Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood (2007) 1.43
Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood (2005) 1.37
Therapeutic targeting of receptor tyrosine kinases in lung cancer. Expert Opin Ther Targets (2005) 1.16
Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma. Clin Cancer Res (2006) 1.10
HKI-272 in non small cell lung cancer. Clin Cancer Res (2007) 1.07
Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res (2007) 1.04
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res (2006) 1.03
c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. Br J Cancer (2007) 0.98
c-Met inhibition. Clin Adv Hematol Oncol (2006) 0.85
Role of c-MET in upper aerodigestive malignancies--from biology to novel therapies. J Environ Pathol Toxicol Oncol (2005) 0.80
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 24.57
Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J (1982) 17.98
The 5' ends of Drosophila heat shock genes in chromatin are hypersensitive to DNase I. Nature (1980) 14.11
The protein information resource (PIR). Nucleic Acids Res (2000) 13.54
Complete genome sequence of Methanobacterium thermoautotrophicum deltaH: functional analysis and comparative genomics. J Bacteriol (1997) 12.21
p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell (1998) 11.54
The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care (1999) 9.16
WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res (1994) 9.00
Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med (2000) 8.47
Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (1997) 7.95
A proteolytic pathway that recognizes ubiquitin as a degradation signal. J Biol Chem (1995) 7.79
The frequency of chimeric molecules as a consequence of PCR co-amplification of 16S rRNA genes from different bacterial species. Microbiology (1996) 7.78
INCREASED ELASTIC TENSION OF THE LUNG IN EXPERIMENTAL PNEUMONIA. J Clin Invest (1932) 7.73
Genetic reassortment of avian, swine, and human influenza A viruses in American pigs. J Virol (1999) 7.72
Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron (1996) 7.20
Frequency of formation of chimeric molecules as a consequence of PCR coamplification of 16S rRNA genes from mixed bacterial genomes. Appl Environ Microbiol (1997) 7.09
A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature (1996) 7.04
Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science (1999) 6.93
Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science (1997) 6.75
TFAR19, a novel apoptosis-related gene cloned from human leukemia cell line TF-1, could enhance apoptosis of some tumor cells induced by growth factor withdrawal. Biochem Biophys Res Commun (1999) 6.33
Two protein-binding sites in chromatin implicated in the activation of heat-shock genes. Nature (1984) 6.19
Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med (1997) 5.93
The chromatin structure of specific genes: I. Evidence for higher order domains of defined DNA sequence. Cell (1979) 5.83
A chromatin remodelling complex involved in transcription and DNA processing. Nature (2000) 5.77
ATP-dependent nucleosome disruption at a heat-shock promoter mediated by binding of GAGA transcription factor. Nature (1994) 5.75
Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell (1996) 5.67
A cluster of hydrophobic amino acid residues required for fast Na(+)-channel inactivation. Proc Natl Acad Sci U S A (1992) 5.60
Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem Biol (1997) 5.49
Deficient hippocampal long-term potentiation in alpha-calcium-calmodulin kinase II mutant mice. Science (1992) 5.46
Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med (2001) 5.43
IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res (1998) 5.41
Genetic diversity and disease control in rice. Nature (2000) 5.34
A role for the lissencephaly gene LIS1 in mitosis and cytoplasmic dynein function. Nat Cell Biol (2000) 5.29
Racial differences in the use of cardiac catheterization after acute myocardial infarction. N Engl J Med (2001) 5.29
Organizing principles for a diversity of GABAergic interneurons and synapses in the neocortex. Science (2000) 5.27
The PIR-International Protein Sequence Database. Nucleic Acids Res (1999) 5.18
The chromatin structure of specific genes: II. Disruption of chromatin structure during gene activity. Cell (1979) 5.13
Induction of sequence-specific binding of Drosophila heat shock activator protein without protein synthesis. Nature (1987) 5.04
HIV-1 inhibition by a peptide. Nature (1993) 5.01
Purification and properties of an ATP-dependent nucleosome remodeling factor. Cell (1995) 4.96
ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol Microbiol (1997) 4.94
Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell (2001) 4.73
Differential signaling via the same axon of neocortical pyramidal neurons. Proc Natl Acad Sci U S A (1998) 4.59
POWER_SAGE: comparing statistical tests for SAGE experiments. Bioinformatics (2000) 4.56
BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci (2001) 4.54
The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature (1998) 4.47
Breaking the integrin hinge. A defined structural constraint regulates integrin signaling. J Biol Chem (1996) 4.45
Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A (1996) 4.45
Bending of DNA by gene-regulatory proteins: construction and use of a DNA bending vector. Gene (1989) 4.41
Molecular cloning and expression of a hexameric Drosophila heat shock factor subject to negative regulation. Cell (1990) 4.40
Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet (1998) 4.38
Do "America's Best Hospitals" perform better for acute myocardial infarction? N Engl J Med (1999) 4.30
The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev (1998) 4.29
Characterization of the imitation switch subfamily of ATP-dependent chromatin-remodeling factors in Saccharomyces cerevisiae. Genes Dev (1999) 4.25
Fringe is a glycosyltransferase that modifies Notch. Nature (2000) 4.09
Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science (1999) 4.08
Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci U S A (1997) 4.07
Activating protein factor binds in vitro to upstream control sequences in heat shock gene chromatin. Nature (1984) 3.92
Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. J Immunol (2001) 3.86
Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. Proc Natl Acad Sci U S A (1994) 3.85
Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci U S A (1998) 3.85
A bacterial artificial chromosome library for sequencing the complete human genome. Genome Res (2001) 3.81
Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc Natl Acad Sci U S A (1996) 3.78
An exonuclease protection assay reveals heat-shock element and TATA box DNA-binding proteins in crude nuclear extracts. Nature (1985) 3.76
Regulation of AMPA receptor-mediated synaptic transmission by clathrin-dependent receptor internalization. Neuron (2000) 3.73
Displacement of sequence-specific transcription factors from mitotic chromatin. Cell (1995) 3.71
Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. Nat Genet (1997) 3.69
The presynaptic particle web: ultrastructure, composition, dissolution, and reconstitution. Neuron (2001) 3.68
Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol (1994) 3.66
Signal timing across the macaque visual system. J Neurophysiol (1998) 3.66
Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J Cell Biol (1985) 3.63
The ISWI chromatin-remodeling protein is required for gene expression and the maintenance of higher order chromatin structure in vivo. Mol Cell (2000) 3.62
Y-Chromosome evidence for a northward migration of modern humans into Eastern Asia during the last Ice Age. Am J Hum Genet (1999) 3.60
The alternative oxidase lowers mitochondrial reactive oxygen production in plant cells. Proc Natl Acad Sci U S A (1999) 3.53
CDKN2A mutations in multiple primary melanomas. N Engl J Med (1998) 3.52
Molecular cloning and expression of a human heat shock factor, HSF1. Proc Natl Acad Sci U S A (1991) 3.47
Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet (2004) 3.45
The ica locus of Staphylococcus epidermidis encodes production of the capsular polysaccharide/adhesin. Infect Immun (1998) 3.44
ISWI, a member of the SWI2/SNF2 ATPase family, encodes the 140 kDa subunit of the nucleosome remodeling factor. Cell (1995) 3.44
Protein traffic on the heat shock promoter: parking, stalling, and trucking along. Cell (1993) 3.43
Cooperative interaction of S. pombe proteins required for mating and morphogenesis. Cell (1994) 3.41
Focal adhesion kinase is involved in mechanosensing during fibroblast migration. Proc Natl Acad Sci U S A (2001) 3.41
A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature (1999) 3.40
Midzone microtubule bundles are continuously required for cytokinesis in cultured epithelial cells. J Cell Biol (1996) 3.36
Criteria and recommendations for vitamin C intake. JAMA (1999) 3.32
Regulation of heat shock factor trimer formation: role of a conserved leucine zipper. Science (1993) 3.31
Stress-induced oligomerization and chromosomal relocalization of heat-shock factor. Nature (1991) 3.29
ATP-dependent histone octamer sliding mediated by the chromatin remodeling complex NURF. Cell (1999) 3.27
Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet (2001) 3.27
Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet (2000) 3.25
Fas-induced caspase denitrosylation. Science (1999) 3.21
Male fertility potential in terms of semen quality: a review of the past, a study of the present. Fertil Steril (1979) 3.19
Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J Biol Chem (1987) 3.19
The rate-pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris. Circulation (1978) 3.19
Differential regulation of circadian pacemaker output by separate clock genes in Drosophila. Proc Natl Acad Sci U S A (2000) 3.11
Identification of toxicants in cinnamon-flavored electronic cigarette refill fluids. Toxicol In Vitro (2014) 3.10